BioTime, Summit Pharmaceuticals deal

The companies partnered to develop BTX's Hextend and PentaLyte plasma extenders in Japan to treat

Read the full 150 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE